Aegis Awarded Patent for Fast Acting Intravail(R)-Based Triptan Nasal Spray Formulations for Treating Migraine Headaches
SAN DIEGO, CA--(Sep 24, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.
The rapidly acting formulations utilize Aegis' patented Intravail® transmucosal absorption enhancer technology.
For comparison, the most widely used triptan formulations, namely sumatriptan nasal spray or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief. In contrast, human clinical data presented in the issued patent shows that the Intravail® formulation of sumatriptan achieves equivalent drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products.
While Aegis now has more than a half dozen issued formulation patents related to peptide and protein therapeutics, this patent marks the first issued patent relating to Intravail® formulations of small molecule drugs. More than three dozen additional US and foreign patent applications relating to small molecule, peptide, protein biotherapeutic, and nucleotide analog drugs are pending.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.
For more information about Aegis, please visit: http://www.aegisthera.com.
Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact